Aditya Bardia, MD
Hematology & Oncology · Santa Monica, CANPI 1639210107
Payments from drug & device makers
Across 1,024 payments — averaging $21,586 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$10.9M
- Pfizer$3M
- Genentech, Inc.$2M
- AstraZeneca$1.6M
- Gilead$1.1M
- Sanofi US Services Inc.$888K
- plus $2.5M from 24 others
Across 102 payments — averaging $866.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$24K
- Novartis$21K
- Pfizer$16K
- Sanofi$9K
- Eli Lilly$6K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- plus $7K from 2 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 75 | $10,936,218 |
| Pfizer | 51 | $2,969,878 |
| Genentech, Inc. | 168 | $2,004,251 |
| AstraZeneca | 60 | $1,645,083 |
| Gilead | 90 | $1,115,676 |
| Sanofi US Services Inc. | 74 | $887,597 |
| Merck | 102 | $759,317 |
| Astrazeneca UK Limited | 50 | $391,133 |
| Roche Products Limited | 55 | $245,813 |
| Daiichi Sankyo Inc. | 40 | $242,878 |
| Radius Health, Inc. | 45 | $207,561 |
| Eli Lilly | 46 | $183,094 |
| Immunomedics, Inc. | 6 | $178,501 |
| Stemline Therapeutics Inc. | 64 | $166,812 |
| Sanofi-aventis U.S. LLC | 13 | $44,934 |
| F. Hoffmann-la Roche AG | 22 | $20,792 |
| E.r. Squibb & Sons, L.L.C. | 10 | $17,726 |
| Lilly USA, LLC | 2 | $15,300 |
| Sanofi | 9 | $14,316 |
| Philips North America LLC | 8 | $13,346 |
| Genentech USA, Inc. | 6 | $9,667 |
| Puma Biotechnology, Inc. | 13 | $9,421 |
| Foundation Medicine, Inc. | 6 | $6,637 |
| Taiho Oncology, Inc. | 2 | $5,768 |
| Seagen Inc. | 2 | $3,648 |
| Daiichi Sankyo Europe GmbH | 1 | $2,500 |
| Daiichi Sankyo Company LTD | 1 | $2,363 |
| Eisai Inc. | 1 | $2,040 |
| Delcath Systems | 1 | $1,200 |
| Aadi Bioscience, Inc. | 1 | $800 |
How this compares
$22,104,270 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Santa Monica
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Zev WainbergSanta Monica$19.3M
- Richard FinnSanta Monica$9.9M
- Aaron LisbergSanta Monica$9.6M
- Steven OdaySanta Monica$3.7M
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Nicholas McAndrewLos Angeles$22.9M
- Joseph TuscanoSacramento$20.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.